Tvardi Therapeutics is trading at $1.99 (+6.26%) ahead of its September 14, 2026 presentation at the H.C. Wainwright Global Investment Conference.
- The presentation is scheduled for 4:30 p.m. ET.
- Recent bullish analyst coverage, including Lucid Capital Markets’ Buy rating and $14 price target, may be supporting sentiment.
- Broader markets are lower, making a company-specific catalyst more likely.